PORTFOLIO NEWS Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific Officer November 29, 2018 Read More » NGM Bio Announces New Histology Data from Phase 2 Trial of NGM282 in Patients with NASH November 9, 2018 Read More » Arcus Biosciences Presents Initial Data from the Phase 1 Dose-Escalation Study of AB122, its anti-PD-1 antibody, at the SITC 2018 Annual Meeting November 9, 2018 Read More » NGM Bio Announces Multiple Presentations at AASLD’s The Liver Meeting®, Including New NASH Histology Data from the Phase 2 Trial of NGM282 and Topline Phase 1b Data for NGM313 November 6, 2018 Read More » Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of Myelofibrosis November 1, 2018 Read More » REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets October 16, 2018 Read More » Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis October 10, 2018 Read More » REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors October 9, 2018 Read More » FLX Bio Named By FierceBiotech as One of its “Fierce 15” Biotech Companies of 2018 October 3, 2018 Read More » NGM Bio Appoints David J. Woodhouse, Ph.D. as Chief Executive Officer and Aetna Wun Trombley, Ph.D. as President and Chief Operating Officer October 1, 2018 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Next »
Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific Officer November 29, 2018 Read More »
NGM Bio Announces New Histology Data from Phase 2 Trial of NGM282 in Patients with NASH November 9, 2018 Read More »
Arcus Biosciences Presents Initial Data from the Phase 1 Dose-Escalation Study of AB122, its anti-PD-1 antibody, at the SITC 2018 Annual Meeting November 9, 2018 Read More »
NGM Bio Announces Multiple Presentations at AASLD’s The Liver Meeting®, Including New NASH Histology Data from the Phase 2 Trial of NGM282 and Topline Phase 1b Data for NGM313 November 6, 2018 Read More »
Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of Myelofibrosis November 1, 2018 Read More »
REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets October 16, 2018 Read More »
Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis October 10, 2018 Read More »
REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors October 9, 2018 Read More »
FLX Bio Named By FierceBiotech as One of its “Fierce 15” Biotech Companies of 2018 October 3, 2018 Read More »
NGM Bio Appoints David J. Woodhouse, Ph.D. as Chief Executive Officer and Aetna Wun Trombley, Ph.D. as President and Chief Operating Officer October 1, 2018 Read More »
